Pacific Biosciences of California introduces HiFi sequencing for comprehensive cancer analysis

Pacific Biosciences of California introduces HiFi sequencing for comprehensive cancer analysis
PacBio HiFi powers cancer analysis

Pacific Biosciences of California is promoting its HiFi sequencing technology as a solution to decode the full spectrum of cancer variation. The company states that the single technology platform can identify structural variants, methylation patterns, RNA isoforms, and fusions in cancer samples.

This announcement positions Pacific Biosciences of California as a key player in the genomics technology market, targeting both researchers and clinicians looking for comprehensive genomic insights into cancer. The company is directing interested parties to its latest brochure for further details on its sequencing capabilities.

Pacific Biosciences’ emphasis on comprehensive cancer profiling builds upon its prior initiatives to integrate automatic epigenetic detection in HiFi sequencing, as detailed in developments enabling automatic epigenetic data in HiFi sequencing runs. The company’s advancements in detecting modifications such as 5mC and 6mA through HiFi sequencing further underscore its drive to deliver deeper and more accurate genomic insights into oncology research.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.